Treatment Options

Treatment Goals

The core goals of ADPKD tratamiento are: slow disease progresión, control complicacións, protect función renal, and maintain calidad de vida. Treatment plans are determined through shared decision-making between the paciente and their nefrólogo, taking into account disease estadio, progresión riesgo, and individual circumstances.

Medication Options

For objective information on each medicamento class — including mechanisms, monitoreo requirements, nefrotoxicidad warnings, and the evidencia boundaries of medicina tradicional china — please refer to the Medication Index. This page provides an overview of the overall tratamiento framework only.

Tolvaptan (V2 Receptor Antagonist)

Tolvaptan is a vasopresina receptor V2 antagonist that slows the growth of volumen total renal (TKV) and the decline of eGFR. It is indicated for adult pacientes at high riesgo of rapid progresión.

• What it does: Slows TKV growth and eGFR decline in pacientes with rapid progresión riesgo.
• What it cannot do: It does not cure ADPKD or eliminate existing quistes.
• Monitoring: Liver function, serum sodio, and uric acid must be monitored regularly throughout tratamiento.
• Not suitable for: Patients with eGFR < 25 mL/min/1.73m², significant hepático impairment, or during embarazo.

ACEI / ARB (Blood Pressure Medication)

Angiotensin-converting enzima inhibitors (ACEI) and ARA-IIs (ARB) are first-line antihypertensive agents for ADPKD. They inhibit the renin-angiotensin system, controlling presión arterial while reducing proteínauria and protecting función renal. They are commonly used in ADPKD pacientes with hipertensión or proteínauria; suitability must be assessed by a physician.

• Risks: Hyperkalemia, transient creatinina elevation, dry cough (ACEI).
• Monitoring: Check creatinina and potasio 1–2 weeks after starting tratamiento or dose changes.

Lifestyle Management

• Blood pressure control — Target < 130/80 mmHg; follow a low-sodio diet.
• Adequate hydration — Maintain sufficient ingesta de líquidos unless your doctor restricts it.
• Moderate ejercicio — Stay active but avoid contact sports and activities with high riesgo of abdominal trauma, which may rupture quistes.
• Avoid nefrotóxico drugs — Use NSAID-class pain relievers with caution; consult your pharmacist or doctor.
• Regular monitoreo — Follow your nefrólogo's recommended schedule for función renal checks.

Kidney Replacement Therapy

When eGFR falls below 15 mL/min/1.73m² or uremic síntomas appear, terapia de reemplazo renal becomes necessary:

• Hemodiálisis — The most commonly used modality, typically performed at a diálisis center.
• Peritoneal diálisis — Can be performed at home, offering more flexibility.
• Kidney trasplante — Generally offers the highest post-trasplante calidad de vida; requires evaluation of donor compatibility and recipient fitness.

Future Directions

Multiple new therapeutic strategies are in ensayo clínicos or investigación and may offer more options for ADPKD pacientes in the future, including the fármaco en investigación pipeline (miRNA-17 inhibitors, somatoestatinaa analogues, PPAR agonists, HDAC6 inhibitors), gen and terapia de precisión (ASO, edición génica, genotype-guided stratification), ingeniería celular y tisular (célula madres, órganooidess, riñón bioartificial), and trasplante/replacement advances (xenotrasplante, riñón artificial implantable, diálisis portátil).

Most of these therapies are not yet approved and the information is for understanding investigación progress only. Do not attempt any unapproved experimental tratamiento on your own. See the Frontier Treatments dedicated page.

Evidence level: C-D (investigación hypotheses/early trials/preclínico/case reports) · Source: KDIGO 2025 ADPKD guía future directions.